Revlimid
Drug
Celgene Corporation
Total Payments
$64.0M
Transactions
39,145
Doctors
7,307
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $740,837 | 194 | 9 |
| 2023 | $1.4M | 209 | 17 |
| 2022 | $1.5M | 559 | 228 |
| 2021 | $1.5M | 1,221 | 683 |
| 2020 | $6.2M | 2,609 | 1,197 |
| 2019 | $12.7M | 10,125 | 3,262 |
| 2018 | $18.1M | 11,107 | 3,875 |
| 2017 | $22.0M | 13,121 | 3,880 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $52.6M | 4,526 | 82.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6.6M | 2,792 | 10.2% |
| Consulting Fee | $2.1M | 944 | 3.3% |
| Travel and Lodging | $1.8M | 3,217 | 2.8% |
| Food and Beverage | $770,110 | 27,064 | 1.2% |
| Education | $73,831 | 597 | 0.1% |
| Charitable Contribution | $25,000 | 1 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $3,750 | 4 | 0.0% |
Payments by Type
Research
$52.6M
4,526 transactions
General
$11.4M
34,619 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Celgene - Connect MM | Celgene Corporation | $5.8M | 2 |
| CC-5013-NHL-008 | Celgene Corporation | $3.4M | 25 |
| CC-5013-NHL-008 - A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicu | Celgene Corporation | $3.2M | 22 |
| Celgene - Connect MDSAML | Celgene Corporation | $2.8M | 0 |
| A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma(CA078-P10) (CC-5013-NHL-008) | Celgene Corporation | $2.3M | 19 |
| RV-CL-MM-BMTCTN-005339 - 1401: Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma with or without Vaccination with Dendritic Cell /Myeloma F | Celgene Corporation | $2.0M | 2 |
| RV-MM-IFM-0444-US | Celgene Corporation | $1.8M | 3 |
| RV-MM-IFM-0444-US - Randomized Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone to High-Dose Treatment With ASCT in the Initial Management of Myeloma in Patien | Celgene Corporation | $1.6M | 0 |
| A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma(CA078-P10) | Celgene Corporation | $1.5M | 0 |
| RV-CL-MM-BMTCTN-005339 | Celgene Corporation | $1.4M | 0 |
| Connect MDS/AML - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry: The purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and tr | Celgene Corporation | $1.3M | 0 |
| Celgene - Connect MDS/AML | Celgene Corporation | $1.2M | 0 |
| RV-CL-MM-PI-004794 - Lenalidomide Maintenance in Plasma Cell Myeloma | Celgene Corporation | $976,773 | 0 |
| A Phase 3B Randomized Study of Lenalidomide (CC-50 | Celgene Corporation | $860,326 | 0 |
| CC-5013-DLC-002 | Celgene Corporation | $722,250 | 2 |
| RV-CL-MM-PI-004794 | Celgene Corporation | $657,665 | 0 |
| CC-5013-DLC-002 - Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemo | Celgene Corporation | $617,557 | 2 |
| Connect MDS/AML | Celgene Corporation | $581,637 | 0 |
| Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects With Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma (CC-5013-DLC-002) | Celgene Corporation | $502,233 | 10 |
| RV-MM-BMTCTN-0494 | Celgene Corporation | $499,043 | 1 |
Top Doctors Receiving Payments for Revlimid
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Cleveland, OH | $48.8M | 4,169 |
| , D.O | Hematology & Oncology | Greenville, SC | $475,918 | 279 |
| , MD | Hematology & Oncology | Boulder, CO | $399,937 | 12 |
| , M.D | Hematology & Oncology | Stanford, CA | $382,827 | 17 |
| , M.D | Medical Oncology | Austin, TX | $268,881 | 6 |
| , M.D | Hematology & Oncology | Sacramento, CA | $250,249 | 150 |
| , M.D | Hematology & Oncology | Los Angeles, CA | $245,235 | 191 |
| , M.D | Hematology & Oncology | Vancouver, WA | $239,762 | 6 |
| , MD | Hematology & Oncology | Newnan, GA | $239,681 | 209 |
| , MD | Internal Medicine | Seattle, WA | $199,406 | 172 |
| , M.D | Hematology | Hackensack, NJ | $193,790 | 154 |
| , MD | Hematology | San Antonio, TX | $179,776 | 4 |
| , MD | Hematology & Oncology | Boston, MA | $179,531 | 31 |
| , M.D | Hematology & Oncology | Washington, DC | $176,891 | 150 |
| , MD | Hematology & Oncology | New Orleans, LA | $156,856 | 126 |
| , M.D | Internal Medicine | Chicago, IL | $152,276 | 150 |
| , M.D | Specialist | Hawthorne, NY | $151,793 | 106 |
| Michael Bishop | Hematology & Oncology | Burr Ridge, IL | $142,649 | 112 |
| , M.D | Specialist | W Hollywood, CA | $142,514 | 85 |
| Saulius Girnius | Hematology & Oncology | Cincinnati, OH | $136,220 | 105 |
| , MD | Internal Medicine | Duarte, CA | $135,988 | 109 |
| , M.D | Hematology & Oncology | Tucson, AZ | $131,901 | 7 |
| , M.D | Hematology & Oncology | Indianapolis, IN | $131,553 | 128 |
| , MD, MSC | Hematology & Oncology | Aurora, CO | $131,047 | 115 |
| , M.D | Hematology & Oncology | Rochester, MN | $126,029 | 14 |
Ad
Manufacturing Companies
- Celgene Corporation $62.8M
- Takeda Pharmaceuticals U.S.A., Inc. $888,787
- E.R. Squibb & Sons, L.L.C. $310,857
Product Information
- Type Drug
- Total Payments $64.0M
- Total Doctors 7,307
- Transactions 39,145
About Revlimid
Revlimid is a drug associated with $64.0M in payments to 7,307 healthcare providers, recorded across 39,145 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2017 to 2024. In 2024, $740,837 was paid across 194 transactions to 9 doctors.
The most common payment nature for Revlimid is "Unspecified" ($52.6M, 82.2% of total).
Revlimid is associated with 20 research studies, including "Celgene - Connect MM" ($5.8M).